What Has Been The Evolution of the Hepatitis C Market in Recent Years?
The hepatitis c market has seen considerable growth due to a variety of factors.
•In recent years, the market size for hepatitis C has witnessed a swift expansion. The market, which is currently valued at $67.17 billion in 2024, is projected to rise to $76.32 billion in 2025, registering a compound annual growth rate (CAGR) of 13.6%.
The factors that have propelled growth in the historic period include practices of blood transfusion, the use of injection drugs, the dearth of sufficient treatment options, and the advent of direct-acting antivirals (DAAs).
What Is the Forecasted Market Size and Growth Rate for The Hepatitis C Market?
The hepatitis c market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations for the Hepatitis C market postulate a swift expansion in the approaching years, increasing to a value of $134.03 billion in 2029 with a compound annual growth rate (CAGR) of 15.1%.
Factors contributing to this projected ascension during the predicted period include global eradication endeavors, advancements in testing and screening methods, an escalation in healthcare expenditure, as well as the incorporation of telemedicine, and the emergence of innovative therapeutic duos. The forecast period also looks forward to the accommodation of affordable and accessible treatment options, a heightened focus on high-risk demographic clusters, improvements in drug formulations, increased collaboration, teamwork and alliances, and the incorporation of telehealth and digital solutions.
What Factors Are Driving Growth In The Hepatitis C Market?
The hepatitis C market is anticipated to expand due to a projected rise in viral infections. The term viral infections delineates invasions caused by a virus within the human body. Hepatitis C therapies work by annihilating the viral infection and reinstating the immune response in patients who have been cleared of the virus. For example, data from August 2024 from the Centers for Disease Control and Prevention, a public health institute based in the United States, showed an increase in individuals affected by Parvovirus B19, a cyclical respiratory viral infection. This increase was seen across all age groups, with a jump from 3% during 2022–2024 to 10% in June 2024. The most substantial increase was noted amongst children aged 5–9 years, where the prevalence escalated from 15% during 2022–2024 to 40% by June 2024. Furthermore, the rate of pooled samples that tested positive for Parvovirus B19 DNA levels saw a considerable rise from 1.5% in December 2023 to 19.9% in June 2024. Consequently, the rise in viral infections is propelling the growth of the hepatitis C market.
What Are The Main Segments Of The Global Hepatitis C Market?
The hepatitis C market covered in this report is segmented –
1) By Type: Chronic Hepatitis C, Acute Hepatitis C, Other Types
2) By Treatment: Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Other Treatments
3) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis
4) By Distribution Channel: Hospital And Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Research Institutes, Home Care Settings
Subsegments:
1) By Chronic Hepatitis C: Genotype 1, Genotype 2, Genotype 3, Genotype 4, Genotype 5, Genotype 6
2) By Acute Hepatitis C: Symptomatic, Asymptomatic
3) By Other Types: Mixed Infections, Superinfection
Pre-Book The Hepatitis C Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Hepatitis C Market?
Innovative advancements in Hepatitis C diagnostic technologies are becoming a trending factor driving the Hepatitis C market. To maintain their market positions, leading firms in the Hepatitis C market are embracing these new technologies. A case in point is F. Hoffmann-La Roche Ltd., a Swiss pharmaceutical and diagnostics enterprise that launched the Elecsys HCV Duo immunoassay in nations recognizing the CE Mark in July 2022. The immunoassay Elecsys HCV Duo now enables the individual and simultaneous determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. This test is capable of pinpointing patients who may be recovering or displaying signs of a chronic infection possibly leading to other illnesses like liver cancer or early-stage conditions.
Who Are the Key Players in the Hepatitis C Market?
Major companies operating in the hepatitis C market include:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffman La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• Sumitomo Corporation
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH.
• Amgen Inc.
• Toray Industries Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Aurobindo Pharma Ltd.
• Cipla Ltd.
• Lupin Limited
• Cadila Healthcare Ltd.
• Biocon Limited
What Is The Most Dominant Region In The Hepatitis C Market?
North America was the largest region in the hepatitis C market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis C market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
